Market Reports Center One Stop Market Reaserch Shop Global Systemic Psoriasis Therapeutics Market Size, Share, Global Insights, Analysis and Outlook, Emerging Trends and Research Report by Market Reports Center Technavio Announces the Publication of its Research Report – Global Systemic Psoriasis Therapeutics Market 2016-2020 Technavio recognizes the following companies as the key players in the global systemic psoriasis therapeutics market: AbbVie, Johnson & Johnson, Celgene, Amgen, and Pfizer. Other Prominent Vendors in the market are: AbGenomics, Almirall, Anacor Pharmaceuticals, ApoPharma, Astellas Pharma, AstraZeneca, Aurinia Pharmaceuticals, Biocon, Biogen Idec, Biotest, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite BioPharma, Cellceutix Corporation, Coherus Biosciences, Creabilis, Crescendo Biologics, Delenex Therapeutics, Dermira, Eli Lilly, F. Hoffmann-La Roche, Forward Pharma, G & W Laboratories, GlaxoSmithKline, Idera Pharmaceuticals, Incyte Corporation, Kadmon, kinetabio, KPI Therapeutics, Kyowa Hakko Kirin, LEO Pharma, Maruho, Merck, Mitsubishi Tanabe Pharma, Moleculin, MorphoSys, Novartis, Pfizer, Prism Pharma, Promius Pharma, Prothena Biosciences, Provectus Biopharmaceuticals, Sandoz, Sun Pharmaceuticals, Takeda Pharmaceuticals, Taro Pharmaceuticals, TFS Corp, Therapeutics, UCB, Valeant Pharmaceuticals, VBL Therapeutics, XenoPort, and Ziarco Pharma. Browse full report with TOC@ https://marketreportscenter.com/reports/328666/global-systemicpsoriasis-therapeutics-market-2016-2020 Commenting on the report, an analyst from Technavio’ s team said: “One trend resulting in the strong growth of this market is the advent of biologics with novel MOA and cell-based strategies. This market is expected to witness the launch of biologic agents that target the disease pathway specifically, including IL-17/IL-17R receptor inhibitors. Drugs such as brodalumab, guselkumab, and tildrakizumab are undergoing Phase III clinical trials. Also, Cosentyx by Novartis is a novel molecule that specifically targets IL-7 and has shown better efficacy and safety results than Enbrel in clinical studies. Similarly, in 2015, Market Reports Center One Stop Market Reaserch Shop Biocon launched Alzumab, which targets the CD6 protein, and in 2016, Eli-Lilly launched lxekizumab, which targets IL-17A receptor inhibitors. According to the report, factors such as the dominance of market by biologics will drive this market’ s growth prospects for the near future. Biologics account for over 18% of the global pharmaceutical sales, outpacing the sales of branded pharmaceuticals. These drugs will continue to outperform other pharmaceuticals in terms of product sales as there is an increasing need for innovative products as effective treatment options for a range of indications. Further, the report states that one challenge impeding this market’ s growth is the physician's reluctance to prescribe biosimilars. Physicians are reluctant to prescribe biosimilars to patients as biologics cannot be substituted with these drugs. Biologics are developed using a living system or a genetically modified organism. A slight variation in the manufacturing process, in terms of conditions and formulation, of biosimilar products can affect the safety and efficacy of the final product. These drugs can also not be used during post-marketing surveillance, as the substitution of drugs is prohibited during this period. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Request A Sample copy of This Report @ https://marketreportscenter.com/request-sample/328666 About the Systemic Psoriasis Therapeutics Market Psoriasis is a commonly diagnosed immune-mediated disease of the skin. In psoriasis, the skin grows fast and causes a build-up of red, thick white, or silvery patches. It modifies the normal cell cycle of the skin such that new cells move to the surface of the skin quickly to form patches called plaques. These plaques are commonly found on the knees, elbows, scalp, hand and feet. The condition mostly occurs among adults (18 years-35 years), but can also be seen in adolescents (12 years-18 years) and children (under 10 years). Psoriasis is more prevalent among Caucasians compared to African-Americans. According to a World Health Organization (WHO) document of 2015, the global prevalence of psoriasis is approximately 2%-3%. However, it is approximately 4.6% in developed countries. In addition, the risk of an individual getting diagnosed with psoriasis is 41% if both parents have psoriasis, 14% in case one parent is affected, and 6% if a sibling has psoriasis. Technavio’ s analysts forecast the global systemic psoriasis therapeutics market to grow at a CAGR of 9.41% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global systemic psoriasis therapeutics market for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the from the sales of branded, generic, and off-label drugs used to treat psoriasis. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the Market Reports Center One Stop Market Reaserch Shop market along with the decline in revenues from the patent expiries of marketed drugs during the forecast period. The market is divided into the following segments based on geography: • Americas • APAC • EMEA Technavio's report, Global Systemic Psoriasis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors • AbbVie • Johnson & Johnson • Celgene • Amgen • Pfizer Other prominent vendors • AbGenomics • Almirall • Anacor Pharmaceuticals • ApoPharma • Astellas Pharma • AstraZeneca • Aurinia Pharmaceuticals • Biocon • Biogen Idec • Biotest • Boehringer Ingelheim • Bristol-Myers Squibb • Can-Fite BioPharma • Cellceutix Corporation • Coherus Biosciences • Creabilis • Crescendo Biologics • Delenex Therapeutics • Dermira • Eli Lilly • F. Hoffmann-La Roche • Forward Pharma • G & W Laboratories • GlaxoSmithKline • Idera Pharmaceuticals Market Reports Center One Stop Market Reaserch Shop • Incyte • Kadmon • kinetabio • KPI Therapeutics • Kyowa Hakko Kirin • LEO Pharma • Maruho • Merck • Mitsubishi Tanabe Pharma • Moleculin • MorphoSys • Novartis • Prism Pharma • Promius Pharma • Prothena Biosciences • Provectus Biopharmaceuticals • Sandoz • Sun Pharmaceuticals • Takeda Pharmaceuticals • Taro Pharmaceuticals • TFS • UCB • Valeant Pharmaceuticals • VBL Therapeutics • XenoPort • Ziarco Pharma Market driver • Dominance of market by biologics • For a full, detailed list, view our report Market challenge • Physician's reluctance to prescribe biosimilars • For a full, detailed list, view our report Market trend • Advent of biologics with novel MOA and cell-based strategies • For a full, detailed list, view our report Key questions answered in this report • What will the market size be in 2020 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? Market Reports Center One Stop Market Reaserch Shop You can request one free hour of our analyst’ s time when you purchase this market report. Details are provided within the report. To Get Discount On The Report @ https://marketreportscenter.com/request-discount/328666 Connect for more details: Sam Collins Market Reports Center 1-646-883-3044 (US) [email protected]
According to the report, factors such as the dominance of market by biologics will drive this market s growth prospects for the near future. Biologics account for over 18% of the global pharmaceutical sales, outpacing the sales of branded pharmaceuticals.
© Copyright 2024 Paperzz
